Oslo, Norway, 10 March, 2023 – AdjuTec Pharma AS is a privately held company developing antibiotic resistance breakers. The company is happy to announce the successful completion of the preclinical toxicology program for our lead product APC148. The program has been performed in collaboration with Evotec at different European facilities. The results clearly define a safe dose for the initiation of the phase 1 program.
Manufacturing of drug substance and drug product have been contracted to European manufacturers, securing a robust a supply chain.
Adjutec has scheduled a meeting with the Swedish medicinal agency before summer to seek advice on the phase 1 protocol. The phase 1 program will start with the recruitment of approximately 80 healthy volunteers at a clinical unit in Uppsala, Sweden. The clinical program will define a safe and effective dose of APC148 and the companion antibiotic. This dose will be verified treating patients in the phase 2/3 program.
“Adjutec raised NOK 52mill in private and public funding in 2021 to execute on the APC148 preclinical program needed for a clinical trial application. Our outstanding team is now delivering on these milestones. Despite Covid19 and logistical challenges, APC148 is still on-track to recruit the first subjects to our phase 1 program in 2023. We’re so exited to get started and to contribute to the clinical pipeline of new innovations in antimicrobial resistance”, comments CEO Bjørn Klem.
Full PR available here